AI Terminal
DIACEUTICS PLC
Report Publication Announcement • Jan 19, 2024
7596_rns_2024-01-19_7aeb3ea7-9e2f-4c47-8479-019cfa8daf12.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1787A
Diaceutics PLC
19 January 2024
Diaceutics PLC - Financial Calendar Update
Belfast and London, 19 January 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to pharma and biotech companies, today announces the following financial calendar events.
· January 30, 2024 - Trading Update for the 12 months ended 31 December 2023
· May 21, 2024 - Preliminary results for the full year ended 31 December 2023
· June 24, 2024 - Annual General Meeting of shareholders
Enquiries:
| Diaceutics PLC | |
| Ryan Keeling, Chief Executive Officer | Tel: +44 (0)28 9040 6500 |
| Nick Roberts, Chief Financial Officer | [email protected] |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison | |
| Nick Harland | |
| Kate Hanshaw | |
| Alma Strategic Communications | Tel: +44(0)20 3405 0205 |
| Caroline Forde | [email protected] |
| Matthew Young | |
| Kinvara Verdon |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCBBGDBCGBDGSI